Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.36 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989423 | 0.89 | GPR142 (0.47) | SCN9ATRPV1GPR142GPR52 | |
| SCHEMBL4988108 | 0.88 | GPR183 (0.36) | EGLN1RPS6KB1CNR2 | |
| SCHEMBL4988794 | 0.86 | TSHR (0.47) | HSD11B1CNR2 | |
| SCHEMBL5142651 | 0.85 | CNR2 (0.37) | CNR2 | |
| SCHEMBL4982513 | 0.85 | L3MBTL1 (0.46) | EGLN1RPS6KB1CNR2 | |
| SCHEMBL4987934 | 0.83 | HSD11B1 (0.45) | SCN9ATRPV1HSD11B1 | |
| SCHEMBL4983580 | 0.80 | LPAR1 (0.39) | — | |
| SCHEMBL4985526 | 0.78 | NPC1 (0.40) | SCN9A | |
| SCHEMBL4983036 | 0.78 | RPS6KB1 (0.49) | RPS6KB1 | |
| SCHEMBL4982880 | 0.78 | L3MBTL1 (0.42) | SCN9ATRPV1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | SCN9A 2164/4885EGLN1 1825/4885RPS6KB1 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.